Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10032058 | 0.90 | HCAR3 (0.49) | KDM4EMAPTNAMPTKMT2AMEN1 | |
| SCHEMBL12646651 | 0.88 | MEN1 (0.40) | KDM4EMAPTNAMPTKMT2AMEN1 | |
| SCHEMBL12590062 | 0.85 | MEN1 (0.41) | KDM4EMAPTNAMPTKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL2057832 | 0.84 | MEN1 (0.40) | KDM4EMAPTNAMPTKMT2AMEN1 | |
| SCHEMBL2057999 | 0.82 | AKT1 (0.46) | KDM4EMAPTNAMPTKMT2AMEN1 | |
| SCHEMBL16731692 | 0.74 | NPSR1 (0.58) | KMT2AMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL12834865 | 0.73 | KDM4E (0.40) | KDM4EMAPTNAMPTKMT2AMEN1 | |
| SCHEMBL32665265 | 0.73 | OPRM1 (0.50) | MAPTNAMPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL24285410 | 0.72 | HCAR3 (0.51) | MAPTHCAR3NNMT | |
| SCHEMBL9610832 | 0.72 | CD274 (0.52) | KMT2AMEN1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487080-B2 | Fluorine-labeled compounds | GENERAL ELECTRIC COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110160430-A1 | FLUORINE-LABELED COMPOUNDS | GENERAL ELECTRIC COMPANY (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010079079-A2 | PDGF-Rβ BINDERS | GENERAL ELECTRIC COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160430-A1 | FLUORINE-LABELED COMPOUNDS | PFAS, DHFR, PAICS | KDM4E 4579/4885MAPT 2125/4885NAMPT 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.